GSK Boosts Stake In Theravance, An Apparent Nod To The Biotech's Respiratory Portfolio
GlaxoSmithKline raises its stake in Relovair partner Theravance to 19% in a $129.4 million investment that extends the biopharma's cash runway.
GlaxoSmithKline raises its stake in Relovair partner Theravance to 19% in a $129.4 million investment that extends the biopharma's cash runway.